Navigation Links
Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate
Date:8/5/2008

-Trial to Examine New Therapeutic Platform in Patients with Cystoid Macular

Edema-

SUNNYVALE, Calif., Aug. 5 /PRNewswire/ -- Icon Bioscience, Inc., (IBI), a privately held ophthalmic pharmaceutical company, announced today that enrollment has been completed in its Phase I clinical trial to assess the safety and efficacy of its lead product, IBI-20089, in patients with cystoid macular edema. This multi-site trial enrolled patients with cystoid macular edema associated with retinal vein occlusion and post operative cataract surgery.

IBI-20089 is a novel drug product based on IBI's proprietary Verisome(TM) drug delivery platform technology, which is optimally suited for application in the ophthalmic market. IBI-20089 is designed to last up to one year with a single intravitreal injection. It uniquely provides physicians the flexibility to tailor the duration of effect for a particular patient. IBI- 20089 is administered as a standard intravitreal injection without the need for additional devices or surgical procedures.

"We are pleased to have reached this important milestone. Our preliminary data confirms the safety and efficacy of our lead product, IBI-20089, as well as the versatility and flexibility of our underlying Verisome(TM) drug delivery technology," said Vernon G. Wong, MD, Founder of Icon Bioscience, Inc. "We believe IBI is creating the future standard of ophthalmic care as evidenced by the development of IBI-20089, the first of many products already in development based on the Verisome(TM) technology."

About Icon Bioscience, Inc.

Icon Bioscience, Inc. (IBI) is a privately held company focused on the development and commercialization of novel ophthalmic pharmaceuticals, based on its proprietary Verisome(TM) drug delivery platform. The Verisome(TM) drug delivery technology encompasses over twenty related but distinct novel and proprietary drug delivery systems optimally suited for application in the ophthalmic market. The nature of ophthalmic disease and the unique anatomical and physiological features of the eye, combined with the extreme fragility of the eye, dictate that identifying the correct pharmaceutical agent for a specific disease state represents only half the solution. The pharmaceutical agent must be delivered in a manner that maximizes clinical efficacy while minimizing costs and adverse effects. IBI's lead product, IBI-20089, is in Phase I clinical trials for the treatment of cystoid macular edema.

Contact: Icon Bioscience, Inc.

William S. (Sandy) White

Phone: 408-734-8188 Ext. 14

Email: sandywhite@iconbioscience.com


'/>"/>
SOURCE Icon Bioscience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals Inc. ... a clinical-stage pharmaceutical company focused on the development ... the Canadian Intellectual Property Office has granted Oramed ... Administration of Exenatide". The patent covers Oramed,s invention ... GLP-1 is an incretin hormone that stimulates ...
(Date:5/6/2017)... Provista , a proven leader in the supply chain industry ... Jim Cunniff as the company,s new president and CEO. ... Provista, including most recently serving as the president and CEO ... He assumed his new role with Provista on May 1, ... says Jody Hatcher , president, Sourcing and Collaboration Services ...
(Date:5/4/2017)... MEMPHIS, Tenn. , May 4, 2017 /PRNewswire/ ... of Infection Control, Ultraviolet-C light as ... demonstrated Tru-D SmartUVC,s ability to reduce bioburden on ... influenced bioburden reduction on high-touch, complex medical equipment ... in surgical infections. "This study further ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... 2017 , ... The CFOs included on this list lead ... the nation and help their organizations navigate the challenges in healthcare today. These ... developing successful hospital and health system strategy. , Becker's Hospital Review has published ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Technique, technique, ... back injury when either lifting weights for strength training and exercise or simply lifting ... Center . , “Body position is everything,” Dr. Chang says. “Improper technique in lifting ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand ... Integration company, announced today that its iClinic V12.2 solution has achieved approval from ... NCQA recently introduced PCMH 2017 standards which emphasize team-based care with a significant ...
(Date:5/23/2017)... ... ... Allegheny Health Network and the Alexis Joy D’Achille Foundation ... at West Penn Hospital , a unique facility that will offer the most ... Construction of the Center is underway with a scheduled opening in the fall of ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May 23, 2017—Total ... according to a Workers Compensation Research Institute (WCRI) study, a contrast from the ... System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical payments for ...
Breaking Medicine News(10 mins):